3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
5
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
106
Carcinoma, Intraductal, Noninfiltrating
6
Neoplasms
4
Neoplasm Metastasis
3
Breast Neoplasms, Male
3
Breast Diseases
3
Breast Carcinoma In Situ
3
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Breast Cancer Metastatic
2
Sexual Dysfunction, Physiological
1
Seizures
1
Multiple Endocrine Neoplasia Type 1
1
Locoregional Recurrence
1
Lethal Congenital Contracture Syndrome 2
1
Inflammatory Breast Neoplasms
1
Hypogonadism
1
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
1
HER2-positive Breast Cancer
1
HER2 Negative Breast Cancer
1
Granulosa Cell Ovarian Cancer
1
Fallopian Tube Neoplasms
1
Erectile Dysfunction
1
Epilepsy
1
Endometrial Stromal Tumors
1
ER+ Breast Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasm Female
1
Interventions
Fulvestrant
8
olaparib
4
Capecitabine
4
pyrotinib
3
Docetaxel
3
toripalimab
2
Vinorelbine
2
Trastuzumab
2
Letrozole
2
Injections
2
Goserelin
2
Alpelisib
2
vandetanib
1
trastuzumab deruxtecan
1
talazoparib
1
sacituzumab govitecan
1
pembrolizumab
1
neratinib
1
liposomal doxorubicin
1
exemestane
1
eribulin
1
dalpiciclib
1
ceralasertib
1
cediranib
1
capivasertib
1
abemaciclib
1
Tablets
1
Paclitaxel
1
Moxifloxacin
1
Lead
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Breast Cancer
×
Anastrozole
×
Clear all
NCT04714619
2023-12-19
CAILA
MedSIR
Phase 2
Terminated
2 enrolled